Form 4: Director Adrienne Graves Receives Opus Genetics Equity

Director Adrienne L. Graves was granted 24,367 restricted stock units in Opus Genetics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Adrienne L. Graves acquired 24,367 shares of common stock in the form of restricted stock units (RSUs).
• The transaction occurred on April 20, 2026.
• The shares were granted at a price of $0, representing equity-based compensation.
• Following this transaction, the reporting person's total beneficial ownership is 127,514 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• None identified.

Risks

• Vesting is subject to the reporting person's continuing service through the vesting date.

Future Outlook

The RSUs vest on the earlier of the one-year anniversary of the grant date or the day prior to the issuer's next annual meeting of stockholders, contingent upon continued service.

Industry Context

StockSavvy.ai notes that director equity grants are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between board members and company performance.

Comparison to Industry Standards

• The grant of restricted stock units to non-employee directors is consistent with standard compensation practices for small-cap biotechnology firms.
• The vesting schedule aligns with typical one-year cliff or annual meeting-based vesting cycles observed in the industry.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation grant.

Next Steps

• Vesting of the 24,367 restricted stock units on the earlier of the one-year anniversary or the day prior to the next annual meeting.

Key Dates

Keywords

Opus Genetics, IRD, Form 4, Insider Trading, Director Compensation, Equity Grant